Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is more or less 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The current opinion among 11 TipRanks analysts is actually for a reasonable Buy rating of shares in CVS Health, with an average price target of eighty four dolars.
The analysts priced targets range from a high of $101 to a low of $61.
In its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management solutions. The Long or retail Term Care segment includes offering of prescription medications as well as assortment of general merchandise.
The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and similar services, which includes medical, pharmacy, dental, behavioural health, medical control abilities. The Corporate segment involves in providing administrative services as well as management. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.